Bionectech

Bionectech has created RXSmart, an AI-powered medication-adherence platform specifically designed for elderly patients suffering from Alzheimer’s, dementia, and chronic diseases.

Alzheimer’s affects more than six million Americans. Among its symptoms is significant cognitive decline. This makes it hard for those suffering from the disease to remember to take their medication. In fact, as many as forty percent of those with Alzheimer’s have trouble sticking with their medication schedule.

Not only does this result in worse outcomes for patients, but it also puts a strain on the U.S. healthcare system. The Centers for Medicare & Medicaid Services estimate that medication non-adherence contributes to as much as $300 billion in annual avoidable healthcare costs.

A failure to take medication regularly isn’t just limited to those with Alzheimer’s, either. Patients with chronic diseases — heart failure, COPD, kidney disease — can have trouble remembering, too. Even elderly people who are relatively healthy can easily forget to take medication with any sort of frequency.

That’s why Bionectech created RXSmart.ai. This AI-driven platform includes specialized caregiver support systems. It also has a simple, easy-to-follow interface that’s designed for those suffering from cognitive decline. AI algorithms also adapt to memory-impaired patients. This comprehensive approach aims to support families managing Alzheimer’s care while providing gentle, memory-friendly medication reminders.

Medication adherence is projected to become a nine-billion-dollar market by 2030. With its platform, Bionectech is targeting the 125 million people who battle chronic diseases, as well as the six million Americans living with Alzheimer’s.

Bionectech is in a pilot-testing program in partnership with the University of Maryland School of Medicine. Its team includes experienced healthcare-technology leaders and practicing physicians.

The Company expects to generate its first revenue upon successful completion of pilot programs and commercial deployment.

Team Background

Ziad Gerges - Founder & CEO

Ziad has extensive experience creating AI-driven healthcare solutions.

In addition to his role with Bionectech, he is a data analyst with the University of Maryland School of Medicine. He’s also a healthcare consultant with the California Association of Health Plans.

Previously, he worked at Placentia-Linda Hospital, working as a data analyst. Before that, he was a managing director with Caprico, a biotech firm specializing in oncology and autoimmune diseases.

Ziad holds a Master’s degree in Biotech from Johns Hopkins, a Master’s degree in Healthcare Administration from West Coast University, and an MD from Walden University.

Luci Gabel - Chief Operating Officer

Luci was an adjunct professor of integrative medicine at The George Washington University School of Medicine and Health Sciences. Prior to that, she was a professor at San Jose State University, teaching exercise physiology.

She holds a Bachelor’s degree in Pre-Medicine from Binghamton University, a Master’s degree in Exercise Physiology from the University of Maryland, and an MBA from Johns Hopkins.

David Finkelshteyn - Chief Technology Officer

In addition to his role with Bionectech, David is CEO of Pivotal AI, an IT-services company focused on AI applications. Before that, he was a data scientist with UralChem, a chemical-manufacturing business, where he also spent time as a project manager.

David was Head of Pharmaceuticals Department at GSM Chemical, a Russia-based chemical-manufacturing company. He earned a Bachelor’s degree and Master’s degree in Physics from Lomonosov Moscow State University.

Co-Investors